Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Cilofexor in Hepatic Impairment
NCT02808312Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of cilofexor in Nonalcoholic steatohepatitis (NASH) and Primary Sclerosing Cholangitis (PSC) (6 cohorts), sponsored by Gilead Sciences. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity and 3 more. Started Jul 2016; status: completed.
02
Drugs
cilofexor
03
Conditions
Nonalcoholic steatohepatitis (NASH)Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT02808312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808312.